SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending as investors debate the significance of recent earnings, marked by strong revenue growth but impacted by a distributor termination fee that will be reimbursed by Pepsi. The community is split, with some viewing the dip as a buying opportunity due to solid fundamentals and long-term growth potential, while others express concern over short-term noise and operational expenses. Discussions also revolve around market share, the Pepsi partnership, and analyst expectations following the earnings call.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid a bidding war for obesity assets, with Novo Nordisk and Pfizer vying for Metsera, driving speculation that Viking could be next. Community members suggest that Viking's pipeline may be undervalued compared to Metsera, while also actively discussing a potential buyout and Phase 3 trial data.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is trending due to a significant price drop, sparking discussions about potential overvaluation and buying opportunities. Community members are debating whether to "buy the dip" or anticipate further declines, with some pointing to UBS's Buy rating and a target set at 150 while others cite concerns of missed revenue. The high trading volume and mixed sentiment highlight the uncertainty surrounding $ELF's short-term trajectory.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

ENVX is trending as investors discuss the potential impact of a delayed commercialization timeline due to required battery chemistry adjustments, sparking debates about management credibility and future revenue. Despite the setback, community members express optimism about a potential product reveal at CES and a committed phone OEM partnership, while others are losing faith and selling their shares. Broader discussions involve speculation about target price, patience for disruptive tech, supply chain diversification and overall market conditions.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending due to mixed reactions to a potential deal with the Trump administration to lower weight loss drug prices, with community members debating the long-term impact on revenue and market share amid increasing competition. The stock is also affected by news of a bidding war with Pfizer for Metsera and recent earnings, with discussions focusing on the company's strategy and future prospects. Discussions also center around reactions to an executive collapsing at a press conference.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions around its financial performance and broader political implications. The community is focused on potential market manipulation, the stock's valuation, and its ties to political events. Ongoing debates encompass government shutdowns and their economic effects.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo ($DUOL) is trending as the community debates its future following a significant drop despite reporting strong earnings, with analysts pointing to weaker-than-expected Q4 bookings. Discussions center on the potential impact of AI on language learning apps and whether Duolingo can maintain its competitive edge. Some traders are eyeing a potential rebound, while others remain skeptical about the company's long-term prospects and valuation.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly ($LLY) is trending amid discussions about its strong position in the weight loss drug market, particularly against Novo Nordisk ($NVO), with many anticipating a positive earnings report. Community members are weighing the potential impact of upcoming announcements and comparing $LLY's prospects against competitors, including potential acquisitions. Traders are actively discussing technical indicators, potential price movements, and strategies involving options, highlighting both bullish and bearish perspectives.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending following an earnings report that beat expectations, with revenue growth attributed to strong customer acquisition and increased demand related to AI and cloud adoption; the community is discussing analyst upgrades and the potential for new highs, with some highlighting the stock's relative strength in the software sector.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRSP is trending amid discussions about its potential for growth and a possible short squeeze, with some investors expressing excitement about upcoming presentations and clinical trial data. Community members are also weighing the impact of recent insider buying and analyst ratings, while noting the stock's historical volatility and long-term potential in gene editing. The stock is also reacting to news of other companies in the same sector, like NTLA.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SRPT 
Mizuho Securities analyst Difei Yang reiterated a Buy rating and $160.00 price target on Sarepta Therapeutics  after the company presented new data from its next-generation exon skipping PPMO at the 30mg dose.

Yang commented, &quot;The data was in line with our &quot;base case&quot; expectations, with exon skipping and dystrophin expression improving vs. the 20mg dose, but remaining below the 10% threshold at 12 weeks. On the safety front, a new side effect of hypomagnesemia was identified in the 30mg dose cohort, and appears manageable with magnesium supplement therapy. Importantly, there were no findings/correlation of this side effect with any kidney toxicity. However, we believe longer follow-up/safety data is needed to completely exclude this risk. Sarepta will now move forward with the 30mg dose in a Part B registrational study&quot;

THERE BY THE GRACE OF GOD, GO I.  I could have very well have owned this at 168 on 1/3/2021. Fortune favors the skittish, impulsive and paranoid

Jostie

jill

j_par19

Full-time Investor

Rickster 4. Retirement

Tracy

StockTwits Web

Sarepta Therapeutics Inc

 
Mizuho Securities analyst Difei Yang reiterated a Buy rating and $160.00 price target on Sarepta Therapeutics  after the company presented new data from its next-generation exon skipping PPMO at the 30mg dose.

Yang commented, "The data was in line with our "base case" expectations, with exon skipping and dystrophin expression improving vs. the 20mg dose, but remaining below the 10% threshold at 12 weeks. On the safety front, a new side effect of hypomagnesemia was identified in the 30mg dose cohort, and appears manageable with magnesium supplement therapy. Importantly, there were no findings/correlation of this side effect with any kidney toxicity. However, we believe longer follow-up/safety data is needed to completely exclude this risk. Sarepta will now move forward with the 30mg dose in a Part B registrational study"

THERE BY THE GRACE OF GOD, GO I.  I could have very well have owned this at 168 on 1/3/2021. Fortune favors the skittish, impulsive and paranoid